News & Perspective

Oct 27, 2014

Oct 27, 2014

CSL-Novartis deal includes US cell-based flu vaccine plant

The $275 million deal will make the company the second leading player in the $4 billion global flu vaccine market.

Feb 14, 2013

Feb 14, 2013

Euro studies show flu vaccine working best against type B

(CIDRAP News) – New European studies reported today in Eurosurveillance suggest that this year's influenza vaccine is providing good protection against influenza B viruses but only moderate protection against type A—findings more or less consistent with earlier results in the United States.

May 18, 2011

May 18, 2011

Experts: Regulatory issues are main reason for keeping smallpox virus

(CIDRAP News) – When the World Health Assembly (WHA) considers the fate of the remaining stocks of smallpox virus this week, the debate is likely to be framed in part by a report from a group of independent experts that says the only strong reason for keeping the virus is to satisfy strict regulatory requirements for new vaccines and antivirals.

Feb 11, 2011

Feb 11, 2011

Study showing high effectiveness for H1N1 vaccine stirs debate

(CIDRAP News) – A recent case-control study estimates that the adjuvanted pandemic H1N1 influenza vaccine used in Canada was effective 93% of the time, a substantially higher figure than seen in several other studies and one that has raised some eyebrows among other flu vaccine researchers.

Jan 25, 2010

Jan 25, 2010

WHO defends pandemic response ahead of Europe hearing

(CIDRAP News) – Just days before a Council of Europe hearing to discuss claims that pharmaceutical companies influenced the World Health Organization's (WHO's) pandemic response, the global body said charges by some European officials that the pandemic is "fake" are "wrong and irresponsible."

Pages

Sort Results

 

Narrow results

by country

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»